Toggle light / dark theme

Rationale engineering generates a compact new tool for gene therapy

Scientists at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard have re-engineered a compact RNA-guided enzyme they found in bacteria into an efficient, programmable editor of human DNA.

The protein they created, called NovaIscB, can be adapted to make precise changes to the genetic code, modulate the activity of specific genes, or carry out other editing tasks. Because its small size simplifies delivery to cells, NovaIscB’s developers say it is a promising candidate for developing gene therapies to treat or prevent disease.

The study was led by Feng Zhang, the James and Patricia Poitras Professor of Neuroscience at MIT who is also an investigator at the McGovern Institute and the Howard Hughes Medical Institute, and a core member of the Broad Institute. Zhang and his team reported their open-access work this month in the journal Nature Biotechnology.


Researchers at MIT and the Broad Institute, led by Professor Feng Zhang, redesign a compact RNA-guided enzyme from bacteria, making it an efficient editor of human DNA.

The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses

In recent years, endocan has emerged as a potential biomarker in various medical conditions. This multifaceted molecule, involved in key processes such as inflammation and endothelial dysfunction, has shown promise in predicting disease progression and therapeutic response across a spectrum of pathologies. However, the heterogeneity of studies and the complexity of endocan’s role in different diseases necessitate a comprehensive review. This umbrella review aimed to systematically synthesize and evaluate the evidence from multiple meta-analyses, offering a view of endocan’s effectiveness as a predictive biomarker in medical diseases.

An extensive search was carried out on March 12, 2024, using the following four databases: PubMed, Scopus, Web of Science, and Cochrane Library. The goal was to identify meta-analyses that assess endocan’s predictive efficacy. The pooled effect size and its 95% confidence interval were taken out of each discovered meta-analysis. Furthermore, power analyses were performed to assess the robustness and dependability of the results. An additional GRADE assessment was carried out to gauge the epidemiological reliability of the findings.

In the final analysis, 12 meta-analyses were included in the current umbrella review. The results showed that there is a significant correlation between a higher endocan level and COVID-19 (SMD: 1.40, 95% CI 0.21–2.58, P = 0.02), followed by chronic kidney disease (SMD: 1.34, 95% CI 0.20 to 2.48, P 0.01), obstructive sleep apnea (SMD: 1.30, 95% CI 1.06–1.54, P 0.01), diabetes mellitus (SMD: 1.00, 95% CI 0.81 to 1.19, P 0.01), coronary artery disease (SMD: 0.99, 95% CI 0.58–1.39, P 0.01), hypertension (SMD: 0.91, 95% CI 0.44–1.38, P 0.01), and preeclampsia (SMD: 0.37, 95% CI 0.13–0.62, P 0.01).

Altered protein translation elongation contributes to brain aging

The GFP gene, which has its origins in jellyfish, expresses proteins that fluoresce when illuminated with certain frequencies of light. Poeschla, of the Mayo Clinic in Rochester, Minnesota, reported his results in the journal Nature Methods.

This function is regularly used by scientists to monitor the activity of individual genes or cells in a wide variety of animals. The development and refinement of the GFP technique earned its scientific pioneers the Nobel prize for chemistry in 2008.

In the case of the glowing cats, the scientists hope to use the GM animals in the study of HIV/AIDS.

Muscle-inspired sheet-like robot navigates the tightest spaces

A POSTECH research team has developed a thin, flexible robotic actuator inspired by human muscle proteins. As thin as paper, yet capable of generating strong forces, this robot can maneuver through tight spaces and manipulate objects, making it suitable for a wide range of applications—from surgical robots to industrial equipment. The study has been published in Nature Communications.

Most conventional robots are built with rigid metal components, giving them strength but limiting their ability to perform delicate motions or operate in confined environments.

In the medical field, there is a growing need for robots that can assist with surgeries inside the . In industrial settings, flexible robots are needed for tasks like inspecting complex machinery or cleaning narrow pipelines. However, technologies that combine both flexibility and strength have been lacking—until now.

In vitro anti-cancer efficacy and phyto-chemical screening of solvent extracts of Kigelia africana (Lam.) Benth

Kigelia africana is a medicinal plant growing naturally in many parts of Africa. In Kenya, a water concoction of the plant is used to treat breast and prostate cancers. Laboratory data on its anti-cancer activity and active principles is limited, hence no scientific rationale for its medicinal use. This study reports on in-vitro toxic activities of dichloromethane and methanol extracts of the plant against human breast cancer cells and phytochemical screening of the two extracts.

Scientists develop microscopic ‘swimming’ discs that could help clean polluted waters: ‘Pave the way for applications’

A team of researchers has created small swimmers that can harvest energy from their surroundings and convert it into movement. The discs, about twice as wide as a human hair, are amazingly partly made from dried food dye, according to a news release from New York University.

The fascinating project includes experts from Harvard, the University of Chicago, and elsewhere.

“The essential new principles we discovered — how to make microscopic objects swim on command using simple materials that undergo phase transitions when exposed to controllable energy sources — pave the way for applications that range from design of responsive fluids, controlled drug delivery, and new classes of sensors, to name a few,” lead researcher Juan de Pablo, from NYU, said in the summary.

Newly discovered ‘sixth sense’ links gut microbes to the brain in real time

In a breakthrough that reimagines the way the gut and brain communicate, researchers have uncovered what they call a “neurobiotic sense,” a newly identified system that lets the brain respond in real time to signals from microbes living in our gut.

The new research, led by Duke University School of Medicine neuroscientists Diego Bohórquez, Ph.D., and M. Maya Kaelberer, Ph.D., published in Nature, centers on neuropods, tiny sensor cells lining the colon’s epithelium. These cells detect a common microbial protein and send rapid messages to the brain that help curb appetite.

But this is just the beginning. The team believes this neurobiotic sense may be a broader platform for understanding how the gut detects microbes, influencing everything from eating habits to mood—and even how the brain might shape the microbiome in return.

First-Of-Its-Kind Vagus Nerve Implant Gets FDA Approval As A Therapy For Rheumatoid Arthritis

The existing treatment options include biological and targeted synthetic disease-modifying anti-rheumatic drugs, which some patients find hard to tolerate, and around 50 percent of patients discontinue their therapies within two years. SetPoint’s goal is to provide an alternative that can effectively manage autoimmune conditions without suppressing the immune system.

Its FDA approval follows a randomized, double-blind, sham-controlled study that followed 242 patients. It showed that the therapy was well-tolerated with a low level of serious adverse events related to it (1.7 percent). It also provides a long-term solution for patients living with this chronic disease.

“The approval of the SetPoint System highlights the potential of neuroimmune modulation as a novel approach for autoimmune disease, by harnessing the body’s neural pathways to combat inflammation,” said the study’s principal investigator, Dr Mark Richardson, Director of Functional Neurosurgery at Massachusetts General Hospital and Professor of Neurosciences at Harvard Medical School, in a statement. “After implantation during a minimally invasive outpatient procedure, the SetPoint device is programmed to automatically administer therapy on a predetermined schedule for up to 10 years, simplifying care for people living with RA.”

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

After transplantation into the brain of patients with Parkinson’s disease, allogeneic dopaminergic progenitors derived from induced pluripotent stem cells survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.

/* */